CompletedNCT03627195

A Study to Determine the Maximum Tolerated Dose of an Investigational Drug in Subjects With Schizophrenia

Medication studyAges 18–65United States

The study in practice

Understand this study

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Study clarity

Study start dateStarted: June 7, 2018

Recruitment status: Completed
Enrollment listed in the registry: 40
Sponsor: Sumitomo Pharma America, Inc.
Sponsor type: Pharmaceutical company
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 1
Locations: United States
Age range: From 18 Years to 65 Years
Official registry ID: NCT03627195
Official title: Show the full official title
A Randomized, Double Blind, Placebo Controlled, Single Ascending Dose Study With Lurasidone Injectable Suspension to Evaluate Safety, Tolerability and Pharmacokinetics in Subjects With Schizophrenia

Completed

Long Beach

FAQ

Who is behind this study?

The study sponsor is Sumitomo Pharma America, Inc., a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including DSP-1349M and placebo.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.